Table 2.
ACIP recommendations for COVID-19 primary series and booster vaccination by age group.
|
Vaccine |
Dose | Interval |
|
|---|---|---|---|
| General population | Immunocompromised | ||
| BNT162b2 and mRNA-1273 (mRNA vaccines) | Dose 1 | Recommended for most. | |
| Dose 2 | 3 (BNT162b2) or 4 (mRNA-1273), up to 8 weeks after dose 1 | 3 (BNT162b2) or 4 (mRNA-1273) weeks after dose 1 | |
| Dose 3 | 5 months after dose 2 | 4 weeks after dose 2 | |
| Dose 4 | 4 months after dose 2 if age >50 years | 3 months after dose 3 | |
| Dose 5 | Not applicable | 4 months after dose 4 | |
| Ad26.COV2.S (JNJ) | Dose 1 | Limited indications (see text) | |
| Dose 2 | 8 weeks after dose 1 | An mRNA vaccine must be used; 4 weeks after dose 1 | |
| Dose 3 | 4 months after dose 2 if age >50 years; only use mRNA vaccines | mRNA vaccine preferred; 8 weeks after dose 2. | |
| Dose 4 | Not applicable | An mRNA vaccine must be used; 4 months after dose 1 | |